AngioDynamics Reports Revenue Decline and Reduced Net Loss in Q3 Fiscal 2025

AngioDynamics, Inc. reported a decrease in revenue for the third quarter of fiscal year 2025, with net sales of $72.0 million, down 4.2% from $75.2 million in the same period last year. For the nine months ending February 28, 2025, revenue also fell by 8.8% to $212.3 million compared to $232.9 million in the prior year. The decline in revenue was attributed to the divestiture of several business lines, including the PICC and Midline businesses, as well as the discontinuation of certain product lines, which collectively impacted sales by approximately $9.2 million and $33.5 million for the respective periods.

Despite the revenue decline, AngioDynamics reported a significant reduction in net loss, which decreased to $4.4 million, or a loss of $0.11 per share, compared to a net loss of $187.7 million, or a loss of $4.67 per share, in the prior year’s quarter. For the nine-month period, the net loss was $27.9 million, down from $170.9 million in the same period last year. The improvement in profitability was largely due to a reduction in operating expenses, including a notable decrease in legal expenses related to prior litigation.

Strategically, AngioDynamics has been undergoing a restructuring of its manufacturing operations, shifting towards an outsourced model while maintaining a presence in Queensbury, NY for select products and services. This restructuring is expected to generate annual cost savings of approximately $15.0 million starting in fiscal year 2027. Additionally, the company has initiated a share repurchase program, allowing for the repurchase of up to $15.0 million of its common stock, with $13.3 million remaining available as of the end of the reporting period.

Operationally, the company reported a mixed performance across its segments. The Med Tech segment saw a 21.3% increase in sales, driven by strong demand for products like Auryon and the thrombus management platform. Conversely, the Med Device segment experienced a 17.6% decline in sales, primarily due to the divestiture of the PICC and Midline businesses. The company’s cash and cash equivalents stood at $44.8 million as of February 28, 2025, down from $76.1 million at the end of the previous fiscal year, reflecting cash used in operations and investments.

Looking ahead, AngioDynamics aims to continue its focus on product innovation and geographic expansion to drive future growth. The company is committed to enhancing its product offerings and improving operational efficiencies while navigating the challenges posed by the current macroeconomic environment, including inflation and supply chain issues. Management remains optimistic about the potential for recovery and growth in both sales and profitability in the upcoming quarters.